QPS Qualitix has opened its China office, built to provide services to the Chinese biopharma industry and multinational biopharma companies operating in China. The new office expands QPS’ presence in Asia Pacific region and builds on its operations in Taiwan and India.
The QPS Qualitix China Office will provide a full range of contract research services, including clinical trial management and regulatory submission preparation. The new China Office will leverage QPS’ global Resources to develop customized offerings in key therapeutic areas, along with Phase II-IV studies, biostatistics, data management, medical writing, vaccines, medical devices and diagnostics.
“The QPS Qualitix China Office will leverage QPS’ quality and training systems to offer customized, high-quality drug development solutions best suited for local Chinese biopharma, as well as global biopharma’s local affiliates,” said Vincent Yen, general manager of QPS Qualitix China. “We have an aggressive growth plan for China and anticipate increasing QPS’ total staff there during 2012 as we look to provide our customers with the solutions they need to succeed in one of the world’s most dynamic marketplaces.”
The new office is located in the Chao Yang District near Beijing, and will be headed by David Hsu, who has extensive clinical research experience with both global pharmaceutical companies and CROs.